Literature DB >> 1380374

Characterization of the receptor mediating relaxation to substance P in canine middle cerebral artery: no evidence for involvement of substance P in neurogenically mediated relaxation.

C M Stubbs1, G J Waldron, H E Connor, W Feniuk.   

Abstract

1. The aim of this study was to characterize the neurokinin receptor which mediates relaxation of dog isolated middle cerebral artery by the use of selective agonists and antagonists and to establish whether substance P is involved in the neurogenically mediated relaxant response in this vessel. 2. Substance P caused concentration-related, endothelium-dependent relaxations of dog isolated middle cerebral artery, contracted with prostaglandin F2 alpha. The selective NK1 receptor agonists, GR73632 and substance P methyl ester (SPOMe), also caused relaxation with similar maximum effects to those of substance P. GR73632 and SPOMe were approximately 20 times and 6 times less potent respectively than substance P. The selective NK2 and NK3 receptor agonists, GR64349 and senktide, were only weakly active in causing relaxation being at least 425 times and 245 times less potent respectively than substance P. 3. The selective NK1 receptor antagonist, GR82334, was a potent, specific, competitive antagonist of the relaxant effects of substance P. In contrast, the selective NK2 receptor antagonist, R396 (10 microM) had no effect on the response to substance P. 4. Electrical field stimulation of dog isolated middle cerebral artery, contracted with prostaglandin F2 alpha, caused neurogenically mediated, non-adrenergic non-cholinergic (NANC) relaxations. These NANC relaxations were unaffected by endothelium removal, GR82334 (10 microM) or by capsaicin (10 microM) treatment. However, the nitric oxide synthesis inhibitor, L-NG-monomethyl arginine methyl ester (L-NMMA) (100 microM) markedly attenuated the response to electrical stimulation. 5. These results suggest that substance P causes relaxation of dog isolated middle cerebral artery via activation of NK1 receptors. However, substance P does not appear to be involved in NANC neurotransmission. In contrast, the marked inhibitory effect of L-NMMA on NANC relaxations implicates nitric oxide in NANC neurotransmission in this vessel.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380374      PMCID: PMC1908684          DOI: 10.1111/j.1476-5381.1992.tb09071.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Effects of capsaicin on vascular smooth muscle.

Authors:  S P Duckles
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-05       Impact factor: 3.000

Review 2.  Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Biochem Pharmacol       Date:  1989-06-01       Impact factor: 5.858

3.  Calcitonin gene-related peptide and vasodilator nerves in large cerebral arteries of cats.

Authors:  A Saito; T Masaki; Y Uchiyama; T J Lee; K Goto
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

Review 4.  New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization.

Authors:  D Regoli; G Drapeau; S Dion; R Couture
Journal:  Trends Pharmacol Sci       Date:  1988-08       Impact factor: 14.819

5.  Competitive antagonists discriminate between NK2 tachykinin receptor subtypes.

Authors:  C A Maggi; R Patacchini; S Giuliani; P Rovero; S Dion; D Regoli; A Giachetti; A Meli
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

6.  The rabbit jugular vein is a contractile NK-1 receptor system.

Authors:  F Nantel; N Rouissi; N E Rhaleb; S Dion; G Drapeau; D Regoli
Journal:  Eur J Pharmacol       Date:  1990-04-25       Impact factor: 4.432

Review 7.  Receptors for substance P and related neurokinins.

Authors:  D Regoli; G Drapeau; S Dion; P D'Orléans-Juste
Journal:  Pharmacology       Date:  1989       Impact factor: 2.547

8.  Cholera and pertussis toxins amplify prostacyclin synthesis in aortic smooth muscle cells.

Authors:  D Demolle; J M Boeynaems
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

9.  Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P.

Authors:  R Uddman; L Edvinsson; R Ekman; T Kingman; J McCulloch
Journal:  Neurosci Lett       Date:  1985-11-20       Impact factor: 3.046

10.  Effects of capsaicin on nonadrenergic noncholinergic nerves in the guinea pig atria: role of calcitonin gene-related peptide as cardiac neurotransmitter.

Authors:  T Miyauchi; T Ishikawa; Y Sugishita; A Saito; K Goto
Journal:  J Cardiovasc Pharmacol       Date:  1987-12       Impact factor: 3.105

View more
  5 in total

1.  Lack of a role for substance P in the control of dural arterial flow.

Authors:  J Carmody; M Pawlak; K Messlinger
Journal:  Exp Brain Res       Date:  1996-10       Impact factor: 1.972

2.  Sensory nerve-mediated relaxation of guinea-pig isolated pulmonary artery: prejunctional modulation by alpha 2-adrenoceptor agonists but not sumatriptan.

Authors:  A Butler; S P Worton; C T O'Shaughnessy; H E Connor
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

3.  Nitric oxide is a mediator of tachykinin NK3 receptor-induced relaxation in rat mesenteric artery.

Authors:  A Mizuta; Y Takano; K Honda; R Saito; T Matsumoto; H Kamiya
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

4.  Lack of effect of sumatriptan and UK-14,304 on capsaicin-induced relaxation of guinea-pig isolated basilar artery.

Authors:  C T O'Shaughnessy; G J Waldron; H E Connor
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

5.  Neurokinin-induced changes in pial artery diameter in the anaesthetized guinea-pig.

Authors:  D T Beattie; C M Stubbs; H E Connor; W Feniuk
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.